{
    "clinical_study": {
        "@rank": "122663", 
        "acronym": "Verona", 
        "arm_group": [
            {
                "arm_group_label": "Perceivable Stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "Stimulation of the occipital nerves."
            }, 
            {
                "arm_group_label": "Non-Perceivable", 
                "arm_group_type": "Active Comparator", 
                "description": "Stimulation of the occipital nerves."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this proof-of-concept study is to generate initial safety and effectiveness\n      data for the neuro-modulation stimulation (NMS) E-Box in patients with chronic migraine in\n      an acute setting. The results of this study will determine if further development of this\n      device in a larger study is warranted."
        }, 
        "brief_title": "Occipital Nerve Stimulation in the Treatment of Migraine", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult \u2265 18 and \u2264 65 years of age females or males;\n\n          2. Willing to participate in the study and to complete  all study-related procedures,\n             evaluations, and headache diaries;\n\n          3. Able to understand, agree to, and sign the study's IRB-approved informed consent\n             form;\n\n          4. Has a physician-made diagnosis of Chronic Migraine as defined by the following (a, b,\n             and c):\n\n               1. Headache (tension-type and/or migraine) lasting a minimum of 4 hours on \u226515 days\n                  per month for at least 3 months and on \u2265XX (redacted by sponsor to preserve\n                  integrity of study) days in the 30 days prior to the Screening Visit;\n\n               2. Headaches on \u22658 days per month for at least 3 months that have fulfilled the\n                  following:\n\n             i. Headaches with at least two of the following:\n\n               -  unilateral location;\n\n               -  pulsating quality;\n\n               -  moderate or severe pain intensity;\n\n               -  aggravation by or causing avoidance of routine physical activity (e.g. walking\n                  or climbing stairs);\n\n             ii. AND at least one of the following:\n\n               -  nausea and/or vomiting;\n\n               -  photophobia and phonophobia;\n\n             iii. OR headaches that have been treated and relieved by triptan(s) or ergot before\n             the expected development of the symptoms listed in 4.b.i and 4.b.ii above;\n\n             c. Headaches are not attributed to a substance or substance withdrawal, infection,\n             cranial neuralgias, cluster headaches, autonomic cephalalgias, or cranial, cervical\n             vascular, non-vascular, intracranial homeostasis and psychiatric disorders;\n\n          5. If taking medication (prescribed or over-the-counter) for migraine prophylaxis, the\n             medication must have been taken for at least 2 months and the dosage(s) must have\n             been stable for at least 1 month prior to the Screening Visit. There must be no plan\n             to add to, discontinue, or change the dose of these medications throughout the\n             subject's participation in the study;\n\n          6. To be eligible for the inpatient Treatment Period: the subject must have recorded in\n             the Headache Diary \u2265XX (redacted by sponsor to preserve integrity of study) headaches\n             days (at least 4 hours of continuous head pain per headache day) in the 30 days\n             immediately prior to the Inpatient Treatment Eligibility Visit (Visit 2);\n\n          7. To be eligible for the inpatient Treatment Period: mean head pain severity of \u2265XX\n             (redacted by sponsor to preserve integrity of study) and \u2264XX (redacted by sponsor to\n             preserve integrity of study) based on the 11-point Numerical Rating Scale (NRS) in\n             the 30 days immediately prior to the Inpatient Treatment Eligibility Visit (Visit 2)\n             [only data from headache days will be used to calculate the mean head pain severity;\n             missing data on a headache day will be considered to be zero (0) for this\n             calculation]; and\n\n          8. To be eligible for the inpatient Treatment Period: The subject must be experiencing\n             head pain on the day of the inpatient Treatment Eligibility Visit (Visit 2).\n             Subjects may continue the Screening Period for another week if head pain is not\n             present at Visit 2.\n\n        Exclusion Criteria:\n\n          1. Any head pain, including coexisting head pain, not attributable to Chronic Migraine\n             as defined in this study's Inclusion Criterion #4;\n\n          2. Any condition that could affect the subject's ability to assess the effect of\n             neurostimulation or in which neurostimulation may be a safety concern, including but\n             not limited to:\n\n               1. Known history of epilepsy or recurrent seizures;\n\n               2. Known neurogenic and neuromuscular disorders (i.e. myasthenia gravis, multiple\n                  sclerosis, autonomic disorders);\n\n               3. Uncontrolled diabetes mellitus;\n\n               4. Known peripheral neuropathy;\n\n          3. History of taking the following medications in the 30 days prior to the Screening\n             Visit:\n\n               1. Opioid and opioid-containing medications;\n\n               2. Butalbital, butalbital-containing, and barbiturate medications;\n\n               3. Systemic corticosteroids (exceptions: acute corticosteroid medication including\n                  inhaled therapy (pulmonary), ocular therapy, or non-spinal intra-articular\n                  therapy);\n\n          4. Urine drug screen that is positive for any of the tested drugs (i.e., cannabis,\n             opiates, barbiturates, amphetamines , benzodiazepines and cocaine) at the Screening\n             Visit (Visit 1) and the Inpatient Treatment Eligibility Visit (Visit 2);\n\n          5. Positive pregnancy test at the Screening Visit (Visit 1) or at the Inpatient\n             Treatment Eligibility Visit (Visit 2);\n\n          6. Known history of cardiac conduction or heart rate abnormalities associated with\n             symptoms;\n\n          7. Uncontrolled hypertension;\n\n          8. Any tattoos or extensive tissue scarring in the cervical/occipital area;\n\n          9. Any active skin lesions, skin damage, broken skin, history of easy bruising or\n             bleeding disorders, or history of surgery and/or trauma in the cervical/occipital\n             area at the time of the Screening Visit;\n\n         10. History of occipital nerve (ON) block, peripheral ON stimulation, or botulinum toxin\n             (e.g., Botox) for treatment of headaches within the 90 days prior to the Screening\n             Visit;\n\n         11. Radiofrequency rhizolysis involving the occipital nerve or cervical nerves;\n\n         12. Surgery involving the occipital nerve or cervical nerves (e.g. neurectomy or\n             rhizotomy), or cervical ganglionectomy;\n\n         13. History of craniotomy or intracranial surgery;\n\n         14. Presence of metallic implant (e.g., metal pin, staple, clip) in the skull or neck\n             area;\n\n         15. Presence of any implanted neuromodulation or cardiac device;\n\n         16. Severe or uncontrolled psychiatric disorders (i.e. schizophrenia, depression,\n             anxiety, or at investigator discretion);\n\n         17. Any other medical condition, concomitant medication or finding for which, at the\n             discretion of the investigator, the subject should be excluded for reasons of safety\n             or capacity for study compliance; or\n\n         18. Participation in any other clinical study (not to include registries or survey-only\n             studies) within 30 days or 5 half lives of an investigational drug, whichever is\n             longer, of Visit 1 (Screening Visit) and for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855672", 
            "org_study_id": "ESC-13-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Perceivable Stimulation", 
                "Non-Perceivable"
            ], 
            "description": "Electrical stimulation of the occipital nerves.", 
            "intervention_name": "Stimulation of the Occipital Nerves", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Migraine, occipital nerve, stimulation", 
        "lastchanged_date": "July 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newington", 
                        "country": "United States", 
                        "state": "New Hampshire"
                    }, 
                    "name": "ActivMed"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Clinilabs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Community Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "TJU"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Controlled, Double-Blind, Proof-of-Concept Study Assessing the Safety and Effectiveness of a Signal Generator Device (NMS EBox) for the Treatment of Chronic Migraine", 
        "other_outcome": {
            "description": "The safety endpoint is to further characterize the safety profile of the NMS E-Box through the collection and evaluation of adverse events.  The occurrence of adverse events will be compared between arms.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Over the treatment and follow-up periods"
        }, 
        "overall_official": [
            {
                "affiliation": "Janssen, LP", 
                "last_name": "David Biondi, DO", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Ethicon, Inc.", 
                "last_name": "Jeff Hammond, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is overall reduction of head pain severity in subjects with chronic migraine who are treated with the NMS E-Box over a 96-hour treatment period.", 
            "measure": "Reduction of Head Pain Severity", 
            "safety_issue": "No", 
            "time_frame": "Over 96-hours treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855672"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Responder rates for reduction in the severity of head pain associated with chronic migraine over the 96-hour Treatment Period (e.g., 30% and 50% responder rates).", 
                "measure": "Rates of Reduction in Severity of Head Pain", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Increase in cumulative time with no head pain over the 96-hour Treatment Period.", 
                "measure": "Time with No Head Pain", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour Treatment Period"
            }, 
            {
                "description": "Decrease in the presence of each of the following migraine-associated symptoms (i.e., nausea or vomiting; photophobia; phonophobia) over the 96-hour Treatment Period.", 
                "measure": "Presence of Symptoms", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Decrease in the severity of each of the following migraine-associated symptoms (i.e., nausea or vomiting; photophobia; phonophobia) over the 96-hour Treatment Period.", 
                "measure": "Severity of Symptoms", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Decrease in the use of any over-the-counter or prescription medication taken for the acute treatment of migraine or head pain over the 96-hour Treatment Period.", 
                "measure": "Use of Medication", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Decrease in Migraine-Related Impairment over the 96-hour Treatment Period.", 
                "measure": "Impairment", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Improvement in Sleep Quality over the 96-hour Treatment Period.", 
                "measure": "Sleep Quality", 
                "safety_issue": "No", 
                "time_frame": "Over the 96-hour treatment period"
            }, 
            {
                "description": "Improvement in the Patient Global Impression of Change (PGIC) for Chronic Migraine at the end of the 96-hour Treatment Period.", 
                "measure": "PGIC", 
                "safety_issue": "No", 
                "time_frame": "End of the 96-hour treatment period"
            }, 
            {
                "description": "Improvement in the Clinician Global Impression of Change (CGIC) for Chronic Migraine at the end of the 96-hour Treatment Period.", 
                "measure": "CGIC", 
                "safety_issue": "No", 
                "time_frame": "End of the 96-hour treatment period"
            }, 
            {
                "description": "Improvement in the Patient Global Impression of Change for Migraine-Related Impairment at the end of the 96-hour Treatment Period.", 
                "measure": "PGIC Migraine", 
                "safety_issue": "No", 
                "time_frame": "End of the 96-hour treatment period"
            }, 
            {
                "description": "Improvement in the Patient Global Impression Change for Sleep Quality at the end of the 96-hour Treatment Period.", 
                "measure": "PGIC Sleep", 
                "safety_issue": "No", 
                "time_frame": "End of the 96-hour treatment period"
            }
        ], 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013", 
        "why_stopped": "Business strategic decision not related to safety."
    }
}